Apolipoprotein C1 (<scp>APOC</scp>1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase <scp>I</scp> trial

Abstract

We found that the level of tumor APOC1 was highly expressed in late stage lung cancer. Further research is warranted to determine the molecular mechanisms underlying the cross talk of APOC1 and IL-6 in tumor progression. An expanded sample size marker phase II study may lead to the discovery of new lung cancer therapeutics targeting APOC1.